CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...